XML 17 R5.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Income - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Revenues:      
Total revenues $ 27,305 $ 24,689 $ 22,449
Costs and expenses:      
Cost of goods sold 6,601 4,572 4,675
Research and development expenses 5,363 5,039 4,055
Acquired in-process research and development expenses 177 5,856 5,051
Selling, general and administrative expenses 5,246 5,151 4,381
Total costs and expenses 17,387 20,618 18,162
Income from operations 9,918 4,071 4,287
Interest expense (1,001) (984) (995)
Other income (expense), net (639) (1,418) 1,868
Income before income taxes 8,278 1,669 5,160
Income tax (expense) benefit (2,077) (1,580) 204
Net income 6,201 89 5,364
Net loss attributable to noncontrolling interest 24 34 22
Net income attributable to Gilead $ 6,225 $ 123 $ 5,386
Net income per share attributable to Gilead common stockholders - basic (in dollars per share) $ 4.96 $ 0.10 $ 4.24
Shares used in per share calculation - basic (in shares) 1,256 1,257 1,270
Net income per share attributable to Gilead common stockholders - diluted (in dollars per share) $ 4.93 $ 0.10 $ 4.22
Shares used in per share calculation - diluted (in shares) 1,262 1,263 1,277
Product sales      
Revenues:      
Total revenues $ 27,008 $ 24,355 $ 22,119
Royalty, contract and other revenues      
Revenues:      
Total revenues $ 297 $ 334 $ 330